Delayed
Japan Exchange
01:24:55 2026-01-13 am EST
5-day change
1st Jan Change
2,881.50 JPY
+1.21%
+3.28%
+4.03%
Published on 01/13/2026
at 01:34 am EST
Publicnow
Notice of Opening of the Tokyo ALC by MEDICEO CORPORATION
– Transferring all functions of the Tokyo Chuo FLC, expanding shipping scale and area, and strengthening the sustainable and stable supply system for prescription pharmaceuticals and other products in the Tokyo metropolitan area –
January 13, 2026 MEDIPAL HOLDINGS CORPORATION
MEDICEO CORPORATION (Head office: Chuo-ku, Tokyo; President and CEO: Kuniaki Imagawa; “MEDICEO”), a consolidated subsidiary of MEDIPAL HOLDINGS CORPORATION (Head office: Chuo-ku, Tokyo; President and CEO: Shuichi Watanabe), has opened a new logistics center, the Tokyo ALC (Area Logistics Center)*1, in Koto Ward, Tokyo, with the aim of strengthening the sustainable and stable supply system for prescription pharmaceuticals and other products in the metropolitan area, and the center launched operations in January 2026.
The MEDIPAL Group has been expanding ALCs nationwide in order to build a system that safely, securely, and efficiently connects pharmaceutical companies to medical institutions in the distribution of pharmaceuticals.
To date, 13 ALCs are in operation (Kanagawa, Minami-Osaka, Nagoya, Sapporo, Tohoku, Minami-Tokyo, Fukuoka, Saitama, Okayama, Minami-Kyushu, Kanto, Hiroshima, and Hanshin (listed in order of completion)), and their highly functional logistics services that improve convenience are being used by many medical institutions. The Tokyo ALC is the 14th ALC location for the MEDIPAL Group.
Since 2013, MEDICEO has been operating the Tokyo Chuo FLC*2 (Front Logistics Center) as one of its core bases in Tokyo. In order to respond to the increase in pharmaceutical distribution volume, future logistics issues, and strengthen our business continuity plan (BCP) in anticipation of emergencies such as earthquakes, MEDICEO has established the Tokyo ALC as a new logistics base by leasing and renovating an existing warehouse property, transferring all functions of the Tokyo Chuo FLC, and expanding the shipping scale and coverage area.
In addition, with this relocation, the Tokyo ALC will become a new urban logistics model, and by accommodating not only MEDICEO but also other MEDIPAL Group companies, it will be further expanded into the group’s first complex center, with the aim of optimizing the overall supply chain and strengthening the business foundation.
The building that was used as the Tokyo Chuo FLC will be temporarily closed and renovated to handle sales functions.
*1 ALC (Area Logistics Center): A state-of-the-art distribution center that supplies prescription pharmaceuticals, medical materials, and clinical diagnostics reagents, etc.
*2 FLC (Front Logistics Center): A sales and distribution base that helps support the stable supply of products in collaboration with ALCs. FLCs are established in areas near our customers.
(Reference) About Tokyo ALC
Exterior of Tokyo ALC
Overview of Tokyo ALC
(1)
Name
Tokyo ALC
(2)
Address
5-29-15 Toyo, Koto-ku, Tokyo
(3)
Site area
6,225.84 ㎡
(4)
Floor area
17,667.09 ㎡
(5)
Structure
Reinforced concrete construction, Flat roof, 6 above-ground floors
Characteristics of Tokyo ALC
Robust BCP (Business Continuity Plan) response to protect the Tokyo metropolitan area As a disaster prevention base located in the eastern part of Tokyo’s 23 wards, we have significantly expanded our pharmaceutical supply functions in the event of an earthquake or other disaster, including expanding the scale and area of shipments. In addition to the seismic isolation structure, we are equipped with a private power generator, allowing us to operate at full capacity for 72 hours even in the event of a power outage. We aim to ensure uninterrupted logistics even in the event of a disaster, and fulfill our responsibility as social infrastructure to protect people’s lives and health.
High delivery accuracy that ensures “security, safety, and high quality”
By combining our long-cultivated logistics know-how with the latest AI technology and material handling equipment, we have created a system that delivers all kinds of products, including pharmaceuticals, securely, safely, and with high quality. We have achieved an extremely high level of delivery accuracy of 99.9997% (6σ: Six Sigma), providing high-quality logistics services to medical institutions.
Utilizing a favorable location to streamline delivery and achieve multiple functions Located in the eastern part of Tokyo’s 23 wards, it has excellent access to major highways. Taking advantage of its strategic location, we have expanded our shipping area. Furthermore, as the first “complex center” that consolidates the functions of each MEDIPAL Group company, we will maximize group synergy and build an efficient delivery network.
High-level logistics functions in compliance with GDP guidelines and environmental considerations
Strict temperature control, counterfeit drug prevention measures, and hygiene management will be implemented in accordance with GDP guidelines*3. In addition, the center will be operated as a next-generation center that combines environmentally friendliness (green logistics) with low-cost operation, through measures such as the introduction of electric vehicles.
*3 GDP guidelines: Guidelines for Good Distribution Practice of Pharmaceuticals issued by the Ministry of Health, Labour and Welfare in 2018
Capital investment
Total of around 1.1 billion yen (Building renovation costs, facilities, equipment, etc. )
Service area
Chiyoda-ku, Chuo-ku, Minato-ku, Bunkyo-ku, Taito-ku, Sumida-ku, Koto-ku, Arakawa-ku, Edogawa-ku, etc.
Shipment amount (at start of operation)
Around 110 billion yen per year (tentative)
Launch of operations
January 2026
About MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO Location: 3-1-1 Kyobashi, Chuo-ku, Tokyo
Scope of business: As a holding company, MEDIPAL HOLDINGS controls, administers and supports the operating activities of companies in which it holds shares in the Prescription Pharmaceutical Wholesale Business; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, and conducts business development for the MEDIPAL Group.
Established: May 1923
Website: https://www.medipal.co.jp/english/
About MEDICEO CORPORATION
Representative: Kuniaki Imagawa, Representative Director, President and CEO Location: 3-1-1 Kyobashi, Chuo-ku, Tokyo
Scope of business: Wholesale of prescription pharmaceutical, medical equipment, medical supplies, clinical testing reagents, etc.
Established: April 2004
Website: https://www.mediceo.co.jp/ (Japanese site only)
CONTACT
MEDIPAL HOLDINGS CORPORATION
Public Relations Department Tel: +81-3-3517-5171
# # #
The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.
Attachments
Original documentPermalink
Disclaimer
Medipal Holdings Corporation published this content on January 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 13, 2026 at 06:33 UTC.
Dec. 14
Nippon Life Insurance Company proposed to acquire 62.19% stake in Medical Data Vision Co., Ltd. from MediPal Holdings Corporation, Hiroyuki Iwasaki and others for ¥40.4 billion.
CI
Nov. 05
Tranche Update on MediPal Holdings Corporation’s Equity Buyback Plan announced on May 13, 2025.
CI
Nov. 05
Medipal Holdings Corp – to cancel 3,251,000 shares of common stock, worth 1.48%, on November 28
RE
Nov. 05
MediPal Holdings Corporation Announces Dividend for the First Half Ended September 30, 2025, Payable on December 2, 2025
CI
25-10-30
MediPal Holdings Corporation’s Equity Buyback announced on May 13, 2025, has closed with 3,251,000 shares, representing 1.57% for ¥7,999.83 million.
CI
25-10-02
Tranche Update on MediPal Holdings Corporation’s Equity Buyback Plan announced on May 13, 2025.
CI
25-09-29
Medipal receives orphan drug designation for JR-446 for mucopolysaccharidosis type IIIB
RE
25-09-29
Medipal Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by Ministry of Health, Labour and Welfare of Japan
CI
25-09-02
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Sign Global Licensing and Japan Co-Development Agreement for JR-479, A Novel Therapy for GM2 Gangliosidosis
CI
25-07-02
Tranche Update on MediPal Holdings Corporation’s Equity Buyback Plan announced on May 13, 2025.
CI
25-06-30
Medipal’s Yoda on Business Strategy
MT
25-05-23
Medipal Holdings Corporation Announces Board Changes
CI
25-05-13
MediPal Holdings Corporation announces an Equity Buyback for 4,000,000 shares, representing 1.92% for ¥8,000 million.
CI
25-05-13
Medipal Holdings Corp – To Buy Back Up To 1.9% Of Own Shares Worth 8 Billion Yen
RE
25-05-13
MediPal Holdings Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026
CI
25-05-13
MediPal Holdings Corporation Announces Dividend for the Year Ended March 31, 2025, Payable on June 3, 2025; Provides Dividend Guidance for the Second Quarter-End of the Year Ending March 31, 2026
CI
25-05-13
MediPal Holdings Corporation Provides Dividend Guidance for the Year Ending March 31, 2026
CI
25-05-12
MediPal Holdings Corporation authorizes a Buyback Plan.
CI
25-04-30
Medipal Holdings Corporation Revises Dividend Guidance for Year Ended March 31, 2025
CI
25-02-11
MediPal Logs 28% Higher Attributable Profit in Nine Months to December 2024
MT
24-12-06
MediPal Holdings Invests to Acquire 20% Stake in Teva Takeda Pharma
MT
24-12-03
Medipal Holdings Corporation and Jcr Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mps IIIB in Japan
CI
24-11-20
Nikkei Edges Lower as Traders Brace for Nvidia Earnings
MT
24-11-19
MediPal Holdings Merges Subsidiaries to Streamline Sales Network, Medical Equipment Business
MT
24-11-01
MediPal Holdings Corporation Announces Dividend for the Second Quarter Ended September 30, 2024, Payable on December 3, 2024
CI
DurationAuto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.
PeriodDayWeek
7459: Dynamic Chart
MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.
More about the company
Sell
Buy
Last Close Price
2,847.00JPY
Average target price
2,536.00JPY
Spread / Average Target
-10.92%
Consensus
OUR EXPERTS ARE HERE FOR YOU
Monday – Friday 9am-12pm / 2pm-6pm GMT + 1
Select your edition
All financial news and data tailored to specific country editions
AloJapan.com